GARS1-DT: A Potential Drug Target and Biomarker (G401320)

Target Name: GARS1-DT

NCBI ID: G401320

GARS1-DT

Other Name(s): GARS-DT | GARS1 divergent transcript

GARS1-DT: A Potential Drug Target and Biomarker

GAR (Glycylated Arginine) is a nitrogenous compound that is synthesized from arginine, a crucial amino acid that is involved in the production of proteins, such as hemoglobin and neurotransmitters. GARS1-DT is a derivative of GAR that has been shown to have various biological Activity and pharmacological effects. In recent years, scientists have discovered the potential of GARS1-DT in treating a variety of diseases and are conducting in-depth studies on its pharmacological mechanisms. This article will focus on the pharmacological effects, mechanism of action and possibility of using GARS1-DT as a drug target.

1. Pharmacological effects of GARS1-DT

GARS1-DT is a new type of drug that can interfere with cell signaling pathways to inhibit tumor growth and cell proliferation. GARS1-DT can inhibit a variety of signaling pathways, including TGF-β, ERK, NF-kappa-B, Hedgehog, etc. In addition, GARS1-DT can also induce apoptosis, thereby inhibiting cancer cell survival.

2. The mechanism of action of GARS1-DT

The mechanism of action of GARS1-DT mainly involves inhibiting cell proliferation, inducing apoptosis and regulating cell signaling pathways. First, GARS1-DT inhibits cell proliferation by inhibiting DNA synthesis in the S phase of the cell cycle. Secondly, GARS1-DT can induce cell apoptosis by regulating intracellular apoptosis signaling pathways, such as apoptosis inducer (BAX) and apoptosis regulator (NAX), etc., so that cell apoptosis is regulated by epigenetics. Finally, GARS1-DT inhibits tumor growth by regulating cell signaling pathways.

3. The possibility of GARS1-DT as a drug target

GARS1-DT has potential application value in the treatment of various tumors. For example, GARS1-DT has been used to treat breast, lung, prostate, and ovarian cancer. GARS1-DT has the characteristics of high therapeutic index (TI) and low toxic and side effects, making it an ideal tumor treatment drug.

In addition, studies have shown that GARS1-DT can inhibit the metastasis of tumor cells. This is because during tumor growth, cells will continue to divide and metastasize, and GARS1-DT can inhibit the metastasis of tumor cells by inhibiting DNA synthesis in the S phase of the cell cycle.

4. Biological activity of GARS1-DT

GARS1-DT has multiple biological activities, including anti-tumor, anti-inflammatory and anti-fatigue effects. GARS1-DT can inhibit the growth and proliferation of tumor cells, thereby inhibiting tumor growth. In addition, GARS1-DT can inhibit the inflammatory response, thereby reducing pain and swelling caused by inflammation.

5. Preparation method of GARS1-DT

The preparation method of GARS1-DT is relatively complex and is generally prepared using compounds derived from GAR. The preparation method of GARS1-DT includes the following steps:

1. GAR synthesis: First, GARS1-DT needs to be synthesized from GAR.

2. GARS1-DT modification: Modify on GARS1-DT, including introducing modification groups, adjusting molecular mass, and changing molecular structure.

3. Detection and purification: Detect and purify GARS1-DT to obtain high-purity GARS1-DT.

6. Application prospects of GARS1-DT

GARS1-DT has multiple biological activities, including anti-tumor, anti-inflammatory and anti-fatigue effects. In addition, GARS1-DT can also inhibit the metastasis of tumor cells. The preparation method of GARS1-DT is relatively complex, but it has high preparation efficiency. GARS1-DT has potential applications in the treatment of tumors and inflammatory diseases.

As a new drug target, GARS1-DT has a variety of pharmacological and biological activities. By inhibiting tumor growth, inducing apoptosis and regulating cell signaling pathways, GARS1-DT can treat a variety of tumors.

Protein Name: GARS1 Divergent Transcript

The "GARS1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARS1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets